1. Home
  2. ANAB vs WLFC Comparison

ANAB vs WLFC Comparison

Compare ANAB & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$63.15

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Willis Lease Finance Corporation

WLFC

Willis Lease Finance Corporation

HOLD

Current Price

$223.88

Market Cap

1.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
WLFC
Founded
2005
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2015
1997

Fundamental Metrics

Financial Performance
Metric
ANAB
WLFC
Price
$63.15
$223.88
Analyst Decision
Buy
Strong Buy
Analyst Count
12
1
Target Price
$71.67
$160.00
AVG Volume (30 Days)
485.4K
109.6K
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
0.86%
EPS Growth
91.02
146.23
EPS
N/A
3.26
Revenue
$234,603,000.00
$569,223,000.00
Revenue This Year
N/A
$2.75
Revenue Next Year
$52.14
$7.35
P/E Ratio
N/A
$68.26
Revenue Growth
157.01
36.00
52 Week Low
$17.11
$114.01
52 Week High
$73.30
$239.44

Technical Indicators

Market Signals
Indicator
ANAB
WLFC
Relative Strength Index (RSI) 59.71 73.67
Support Level $52.32 $165.65
Resistance Level $67.69 $239.44
Average True Range (ATR) 3.05 9.35
MACD 0.99 4.46
Stochastic Oscillator 93.72 91.23

Price Performance

Historical Comparison
ANAB
WLFC

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

Share on Social Networks: